Onconetix Inc. Finalizes $12.9 Million Financing
Onconetix, Inc. (NASDAQ: ONCO), a pioneering biotechnology company, has successfully completed a substantial financing transaction amounting to $12.9 million. This private placement involves both shares of Series D Preferred Stock and tradable warrants, reinforcing the company’s strategy for growth in the men's health and oncology sectors.
Details of the Financing Transaction
The financing includes an issuance of Series D Convertible Preferred Stock and warrants which allow investors to purchase up to 4,362,827 shares of common stock, effectively enhancing Onconetix's financial flexibility. Out of the total proceeds, around $9.3 million was paid out in cash, with the remaining funds structured to alleviate certain financial obligations linked to existing investors.
Usage of Proceeds
As part of its strategic financial management, Onconetix will allocate approximately $6.3 million from the financing to fully settle an outstanding debt of about $8.8 million owed to Veru, Inc. The company is also converting a portion of this debt into shares, as it seeks to optimize its balance sheet and capital structure.
Shareholder Engagement
Another key aspect of this financing is the company’s commitment to shareholder engagement; it plans to seek approval from its stockholders for the issuance of shares linked to the Series D Preferred Stock and warrants. This move aligns with regulatory obligations under the Nasdaq Stock Market rules, ensuring continued compliance and transparency.
Impact of Termination of Merger Agreement
In a strategic pivot, Onconetix has also decided to terminate a previously proposed merger with Ocuvex, Inc. This decision enables the company to focus on existing projects, especially the commercialization of its prostate cancer diagnostic test, Proclarix. By refocusing resources towards core operations, Onconetix aims to streamline its efforts and enhance shareholder value.
Proclarix – A Focused Product Offering
Proclarix is noteworthy for being recognized under the IVDR regulations in the European Union and provides innovative solutions for prostate cancer diagnostics. This product exemplifies Onconetix's dedication to advancing men's health care through cutting-edge technology.
Investor Relations and Future Outlook
Onconetix is committed to maximizing its future growth potential while navigating the biotechnology landscape. With the recent financing, the company is well-equipped to proceed with its operational goals, increase its market presence, and potentially introduce new projects in the pipeline. The firm plans to use the remaining financing proceeds for general corporate purposes and to manage costs associated with the merger termination.
Contact Details
For further inquiries, Onconetix invites stakeholder engagement through its investor relations team. Interested parties can reach out via email or phone to discuss potential opportunities and insights regarding the company's future trajectories.
Frequently Asked Questions
What is the amount raised in the recent financing by Onconetix?
Onconetix raised approximately $12.9 million through a combination of Series D Preferred Stock and warrants.
How will Onconetix utilize the proceeds from the financing?
The proceeds will primarily settle outstanding debt to Veru, Inc. and support general corporate expenses.
What product is Onconetix focusing on?
The company is focused on Proclarix, a diagnostic test for prostate cancer, which is approved in the European Union.
What recent corporate action did Onconetix take regarding Ocuvex?
Onconetix has terminated its merger agreement with Ocuvex, Inc., allowing a sharper focus on existing product offerings.
How can investors contact Onconetix for more information?
Investors may reach Onconetix at their contact number or through their investor relations email.
